Sagility Limited (NSE: SAGILITY, BSE: 544282) is a fundamentally strong, but not low‑risk, midcap IT‑enabled services name. At the latest available price zone around ₹49–50 (close as of 11–12 Dec 2025), it looks reasonably valued for long‑term, high‑risk investors who are comfortable with US healthcare exposure and midcap volatility. I do not have tick‑by‑tick live prices; please confirm the exact CMP on your broker/NSE/BSE screen before acting. (economictimes.indiatimes.com)

Below is a concise, decision‑oriented view.

1. Business & earnings quality

- Pure‑play, healthcare‑focused BPM/ITeS provider, largely servicing US payers/providers – a niche with high entry barriers but regulatory dependence on US healthcare policy. (business-standard.com)

- Q2 FY26 (Sep‑25) results were strong:

- Revenue ~₹1,658 crore, up ~25% YoY; organic growth ~16% YoY.

- Adjusted EBITDA margin ~26%; adjusted PAT margin ~18%, with PAT growth ~80%+ YoY. (business-standard.com)

- High and stable margins put it in the better tier of BPM players, and H1 FY26 also shows >25% revenue growth with strong profitability. (investywise.com)

Implication: Earnings momentum and margin profile are strong; business quality is above average for the sector.

2. Valuation at current levels

- CMP zone: ~₹49–50; market cap about ₹23–23.5k crore. (economictimes.indiatimes.com)

- TTM EPS ~₹1.7; TTM P/E is in the mid‑20s to high‑20s depending on data source (roughly 25–29x). (economictimes.indiatimes.com)

- P/B around 2.7x; dividend yield is very low (~0.1%). (economictimes.indiatimes.com)

- 52‑week range: approx. ₹37.6 – ₹57.9, so CMP is below recent highs but well above the lows and IPO price of ₹30. (business-standard.com)

Implication: For a 25%+ growth/ high‑margin BPM company, this valuation is not cheap but broadly reasonable. Not a deep‑value play; more a growth‑at‑reasonable‑price (GARP) profile.

3. Ownership, flows and broker stance

- Promoter holding has come down from ~82% to ~67% over FY25, with rising institutional and MF ownership (MFs now ~9%, FIIs ~5.5%). (upstox.com)

- A large promoter stake sale of ~16.4% recently happened around ₹47–48 per share via block/OFS; some of this was absorbed by domestic and global institutional investors. (moneycontrol.com)

- Multiple brokerages (Jefferies, JM Financial and others) have initiated/maintained ‘Buy/Strong Buy’ ratings with target prices above CMP (examples quoted in media reports are ₹52–66). (business-standard.com)

Implication: Supply from promoters has been a technical overhang, but increasing institutional ownership and big‑ticket block absorption are positives for liquidity and market perception.

4. Key positives if buying at CMP

1. Strong growth & margins: 20–25% revenue growth with mid‑20s EBITDA margin and rising PAT margins is attractive versus many IT/BPM peers. (business-standard.com)

2. Sector tailwind: US healthcare outsourcing is a large and growing space; Sagility’s long‑tenure client relationships position it well. (business-standard.com)

3. Improving balance sheet: Low debt (D/E ~0.14) and high cash‑generation support future growth and potential for higher payouts over time. (livemint.com)

4. Institutional backing: Rising MF/FII stakes often indicate institutional conviction and can support valuations. (upstox.com)

5. Key risks / when to be cautious

1. US concentration risk: Heavy dependence on US healthcare; any adverse US regulatory or reimbursement change can hit volumes and pricing. (business-standard.com)

2. Promoter selling overhang: Large stake sales can create intermittent supply and price volatility, even if blocks are absorbed. (moneycontrol.com)

3. Midcap IT/BPM cyclicality: If global IT/BPM spending slows or risk‑off hits midcaps, Sagility can correct sharply despite good fundamentals. (livemint.com)

4. Short listed history: The stock listed only in Nov‑2024; there is limited long‑term track record as a standalone listed entity. (business-standard.com)

5. Low yield: Dividend is negligible; returns will primarily depend on earnings growth and re‑rating, not income. (livemint.com)

6. Illustrative view (not investment advice)

- For a long‑term, high‑risk investor (example):

If you are comfortable with (a) sector concentration in US healthcare, (b) midcap volatility, and (c) a 3–5 year horizon, Sagility at ~₹50 can be considered reasonably priced given its growth and margins, especially with recent OFS/blocks priced in the high‑40s. In such a case, a staggered approach (partial allocation now, adding on 10–15% dips) is often safer than lump‑sum buying.

- For conservative or short‑term traders (example):

The stock’s sharp moves around news, ongoing supply from promoters, and relatively rich valuations mean downside volatility can be high; such profiles might prefer to avoid or treat it only as a trading name with strict stop‑losses rather than a core holding.

This is an analytical view only and not a direct recommendation to buy/sell. You should align any action with your risk profile, time horizon and asset allocation, and consider taking SEBI‑registered investment advice before committing capital.

If you have any further queries, please connect with us on 022-6290-10141 (Timings : 09.00 AM to 05.00 PM) or you can email us on info@cniinfoxchange.com